Comparison of Diagnosing and Staging Accuracy of PET (CT) and MIBG on Patients with Neuroblastoma: Systemic Review and Meta-analysis

Overview

Journal J Huazhong Univ Sci Technolog Med Sci

Specialty General Medicine

Date 2017 Oct 24

PMID 29058276

Citations 7

Authors

Jia Xia

Hang Zhang

Qun Hu

Shuang-You Liu

Liu-Qing Zhang

Ai Zhang

Xiao-Ling Zhang

Ya-Qin Wang

Ai-Guo Liu

Affiliations

Soon will be listed here.

Abstract

To perform a systemic review and meta-analysis of the diagnostic accuracy of PET (CT) and metaiodobenzylguanidine (MIBG) for diagnosing neuroblastoma (NB), electronic databases were searched as well as relevant references and conference proceedings. The diagnostic accuracy of MIBG and PET (CT) was calculated for NB, primary NB, and relapse/metastasis of NB based on their sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUSROC) in terms of per-lesion and per-patient data. A total of 40 eligible studies comprising 1134 patients with 939 NB lesions were considered for the meta-analysis. For the staging of NB, the per-lesion AUSROC value of MIBG was lower than that of PET (CT) [0.8064±0.0414 vs. 0.9366±0.0166 (P<0.05)]. The per-patient AUSROC value of MIBG and PET (CT) for the diagnosis of NB was 0.8771±0.0230 and 0.6851±0.2111, respectively. The summary sensitivity for MIBG and PET (CT) was 0.79 and 0.89, respectively. The summary specificity for MIBG and PET (CT) was 0.84 and 0.71, respectively. PET (CT) showed higher per-lesion accuracy than MIBG and might be the preferred modality for the staging of NB. On the other hand, MIBG has a comparable diagnosing performance with PET (CT) in per-patient analysis but shows a better specificity.

Citing Articles

Unusual Location of Neuroblastoma: A Report of Two Cases.

Al Dhuhli A, Al Shuaili I, Abu Qasida K Cureus. 2024; 16(9):e70486.

PMID: 39479120 PMC: 11522949. DOI: 10.7759/cureus.70486.

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses.

Treglia G, Sadeghi R, Giovinazzo F, Galiandro F, Annunziata S, Muoio B Cancers (Basel). 2021; 13(20).

PMID: 34680321 PMC: 8533943. DOI: 10.3390/cancers13205172.

Diagnostic Value of Seven Different Imaging Modalities for Patients with Neuroblastic Tumors: A Network Meta-Analysis.

Wang Y, Xu Y, Kan Y, Wang W, Yang J Contrast Media Mol Imaging. 2021; 2021:5333366.

PMID: 34548851 PMC: 8429030. DOI: 10.1155/2021/5333366.

Diagnostic Performance of F-FDG PET(CT) in Bone-Bone Marrow Involvement in Pediatric Neuroblastoma: A Systemic Review and Meta-Analysis.

Sun L, Zhang B, Peng R Contrast Media Mol Imaging. 2021; 2021:8125373.

PMID: 34220381 PMC: 8221854. DOI: 10.1155/2021/8125373.

Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma.

Man S, Yan J, Li J, Cao Y, Hu J, Ma W Int J Med Sci. 2021; 18(8):1857-1865.

PMID: 33746603 PMC: 7976578. DOI: 10.7150/ijms.58263.

References

Fischer M, Galanski M, Winterberg B, Vetter H . Localization procedures in pheochromocytoma and neuroblastoma. Cardiology. 1985; 72 Suppl 1:143-6. DOI: 10.1159/000173961. View

Edeling C, Frederiksen P, Kamper J, Jeppesen P . Diagnosis and treatment of neuroblastoma using metaiodobenzylguanidine. Clin Nucl Med. 1987; 12(8):632-7. DOI: 10.1097/00003072-198708000-00011. View

Piccardo A, Puntoni M, Lopci E, Conte M, Foppiani L, Sorrentino S . Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol Imaging. 2014; 41(6):1046-56. DOI: 10.1007/s00259-014-2691-0. View

Hammami H, Hassine L, Mhiri A, Sellem A, Oubich F, Gharssallah L . [Metaiodobenzylguanidine scintigraphy in the diagnosis and followup of neuroblastoma. Apropos of 16 cases]. Tunis Med. 2007; 85(5):413-6. View

Lopci E, Piccardo A, Nanni C, Altrinetti V, Garaventa A, Pession A . 18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR. Clin Nucl Med. 2012; 37(4):e73-8. DOI: 10.1097/RLU.0b013e3182485172. View

Erttmann R, Helmke K . [Scintigraphy with radioiodinated meta-iodobenzylguanidine in the diagnosis of neuroblastoma]. Nuklearmedizin. 1985; 24(5-6):222-6. View

Melzer H, Coppenrath E, Schmid I, Albert M, von Schweinitz D, Tudball C . ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011; 38(9):1648-58. DOI: 10.1007/s00259-011-1843-8. View

Matthay K, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V . Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010; 102(9):1319-26. PMC: 2865749. DOI: 10.1038/sj.bjc.6605621. View

Okuyama C, Ushijima Y, Sugihara H, Okitsu S, Maeda T . [123I-metaiodobenzylguanidine (MIBG) scintigraphy for the staging of neuroblastoma]. Kaku Igaku. 1999; 35(9):835-42. View

10.

Shah Syed G, Naseer H, Usmani G, Cheema M . Role of iodine-131 MIBG scanning in the management of paediatric patients with neuroblastoma. Med Princ Pract. 2004; 13(4):196-200. DOI: 10.1159/000078315. View

11.

Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F . Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003; 30(5):B45-50. DOI: 10.1007/s00259-003-1138-9. View

12.

Lu M, Liu Y, Chang H, Jou S, Yang Y, Lin K . Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med. 2012; 54(1):42-9. DOI: 10.2967/jnumed.112.102772. View

13.

Hashimoto T, Koizumi K, Nishina T, Abe K . Clinical usefulness of iodine-123-MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey. Ann Nucl Med. 2004; 17(8):633-40. DOI: 10.1007/BF02984968. View

14.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

15.

Pfluger T, Schmied C, Porn U, Leinsinger G, Vollmar C, Dresel S . Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol. 2003; 181(4):1115-24. DOI: 10.2214/ajr.181.4.1811115. View

16.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

17.

Lebtahi N, Delaloye A, Laurini R, Beck D . Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med. 1995; 22(4):322-9. DOI: 10.1007/BF00941848. View

18.

Labreveux de Cervens C, Hartmann O, Bonnin F, Couanet D, Valteau-Couanet D, Lumbroso J . What is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?. Med Pediatr Oncol. 1994; 22(2):107-14. DOI: 10.1002/mpo.2950220209. View

19.

Hadley G, Rabe E . Scanning with iodine-131 MIBG in children with solid tumors: an initial appraisal. J Nucl Med. 1986; 27(5):620-6. View

20.

Caballero O, Ferris J, Verdeguer A, Esquembre C, Castel V . Iodine-131 metaiodobenzylguanidine. J Nucl Med. 1986; 27(6):868-9. View